Treatment of vascular vertigo in outpatients: Multicentre experience (VascVert study);La terapia della vertigine vascolare nella pratica ambulatoriale: Esperienza multicentrica (VascVert Study)

Otorinolaringologia

Volumn 55, Issue 4, 2005, Pages 237-246

  Guidetti, G ^a  

^a AUSL Modena   (Italy)

Author keywords

Acetil salicylic acid; Dizziness; Sulodexide; Vascular diseases; Vertigo

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; SULODEXIDE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; BODY EQUILIBRIUM; CAROTID ARTERY DISEASE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISABILITY INDEX; DIZZINESS HANDICAP INVENTORY; DRUG MECHANISM; FAMILY HISTORY; FEMALE; HEADACHE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOACUSIS; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MULTICENTER STUDY; OUTPATIENT; PHYSICAL EXAMINATION; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE AGGREGATION; TINNITUS; TREATMENT OUTCOME; VASCULAR VERTIGO; VERTIGO;

EID: 32244447822     PISSN: 00264938     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Grad A, Baloh W. Vertigo of vascular origin. Arch Neurol 1989;46:281-4.
2. Troost BT. Dizziness and vertigo in vertebrobasilar disease. Stroke 1980;11:4132-45.
3. Baloh R. Vertigo. Lancet 1998;352:1841-6.
4. Baloh R. Differentiating between peripheral and central causes of vertigo. Otolaryngol Head Neck Surg 1998;119:55-9.
5. Tirelli G, Meneguzzi C. Orientamento clinico-diagnostico sulla vertigine da causa vascolare. Otorinolaringologia 2004;54:1-10.
6. Walters R, Holmes P, Thomas D. Silent cerebral ischaemic lesions and atrophy in patients with apparently transient cerebral ischaemic attacks. Cerebrovasc Dis 2000;10:11-4.
7. Kikuchi S, Kaga K, Yamasoba T. Slow blood flow of the vertebrobasilar system in patients with dizziness and vertigo. Acta Otolaryngol 1993;113:257-60.
8. Baloh R. Vertebrobasilar insufficiency and stroke. Otolaryngol Head Neck Surg 1995;1122:114-7.
9. Barbanti M, Guizzardi S, Calanni F, Marchi E, Babbini M. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992;22:179-84.
10. Ceriello A, Quatraro A, Marchi E, Barbanti M, Giugliano D. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus:effects of the glycosaminoglycan sulodexide. Diabete Metab 1993;19:225-9.
11. Cerletti C, Rajtar G, Marchi E, De Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost 1994;20:245-53.
12. Parnetti L, Mari D, Abate G, Balestreri R, Cucinotta D, Coppola R et al. Vascular dementia italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Thromb Res 1997;87:225-33.
13. Tirelli G, Zarcone O, Giacomarra V, Bianchi M. La vertigine da causa vascolare: ipotesi patogenetiche e considerazioni terapeutiche. Otorinolaringologia 2001;51:61-8.
14. Cupido G, Restivo S, Giuliano DA, Speciale R, Cupido F. Impiego del sulodexide nel trattamento delle turbe dell'equilibrio: nostra esperienza. Valsalva 2001;77:11-20.
15. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004;92:1175-81.
16. Kirshner HS. Medical prevention of stroke, 2003. South Med J 2003;96:354-8.
17. Cazals Y. Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol 2000;62:583-631.
18. Brien JA. Ototoxicity associated with salicylates. A brief review. Drug Saf 1993;9:143-8.
19. Boettcher FA, Salvi RJ. Salicylate ototoxicity: review and synthesis. Am J Otolaryngol 1991;12:33-47.
20. Steinhubl SR. Antiplatelet therapy: aspirin. J Invasive Cardiol 2003;15 Suppl B:11B-16B; discussion 16B.
21. Kimmey MB. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance. Am J Med 2004;117 Suppl 5A:72S-8S.
22. Hamad AM, Clayton A, Ismal B, Knox AJ. Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 2004;64: 2417-32.
23. Bendixen BH, Adams HP. Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke. Eur Neurol 1996;36: 256-7.
24. Noble S, Goa KL. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 1996;8:444.
25. Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E et al. Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol 2002;71:24-32.
26. Gary PJ, Cralg WN. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990;116:424-7.
27. Monzani D, Casolari L, Guidetti G, Rigatelli M. Psychological distress and disability in patients with vertigo. Psychosom Res 2001;50: 319-23.
28. Guidetti G, Gioffre P, Galetti G. [Disability: a proposal for an anamnestic questionnaire in the evaluation of the degree of disability caused by disorders of equilibrium.] Acta Otorhinolaryngol Ital 1994;14:477-87. Italian.
29. Palmieri L, Trojani M, Vanuzzo D, Panico S, Pilotto L, Dima F et al.; Gruppo di Ricerca dell'Osservatorio Epidemiologico Cardiovascolare. [Distribution of the global cardiovascular risk in the Italian population: results from the cardiovascular epidemiologic observatory] Ital Heart J 2005;6:279-84. Italian.